Drugs / SPN-817
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT07141329 | Jul 2025 → Dec 2027 expected | focal epilepsy | Supernus Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06798896 | Dec 2024 → Aug 2027 expected | focal epilepsy | Supernus Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT05518578 | Feb 2023 → Dec 2027 expected | epilepsy | Supernus Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 0 | NCT05102552 Comparator | Oct 2021 → Mar 2022 | — | Supernus Pharmaceuticals, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2024-11-04 | Supernus Pharmaceuticals, Inc. | Results Supernus Announces Third Quarter 2024 Financial Results supernus.com ↗
The Company has now completed enrollment of Stage A and is reporting topline data from all subjects with focal seizures who received the 3mg and 4mg twice daily doses, completed the maintenance period (n=10), and enrolled in the post-maintenance extension period (n=6). |
| 2024-08-06 | Supernus Pharmaceuticals, Inc. | Results Supernus Announces Second Quarter 2024 Financial Results supernus.com ↗
We also advanced our product pipeline, announcing interim results from our open-label Phase 2a clinical study of SPN-817 for treatment-resistant seizures, and continued to progress SPN-820 through two Phase 2 studies in patients with depression," said Jack Khattar, President and CEO of Supernus. |
| 2024-05-23 | Supernus Pharmaceuticals, Inc. | Results Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy supernus.com ↗
75% median focal seizure reduction at the 3mg to 4mg twice daily doses in the maintenance period. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-11-04 | Supernus Pharmaceuticals, Inc. | Supernus Announces Third Quarter 2024 Financial Results supernus.com ↗ |
| 2024-08-06 | Supernus Pharmaceuticals, Inc. | Supernus Announces Second Quarter 2024 Financial Results supernus.com ↗ |
| 2024-05-23 | Supernus Pharmaceuticals, Inc. | Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy supernus.com ↗ |
| 2024-05-09 | Supernus Pharmaceuticals, Inc. | Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures supernus.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SPN-817 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05518578 ↗ |
| Action | Inhibit | “an acetylcholinesterase inhibitor” NCT05102552 ↗ |
| Route | Oral | “0.25 mg to 4 mg SPN-817 taken orally twice daily” NCT05518578 ↗ |